Joel S Karliner
Overview
Explore the profile of Joel S Karliner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2234
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goetzl E, Goetzl L, Karliner J, Tang N, Pulliam L
FASEB J
. 2016 Feb;
30(5):2058-63.
PMID: 26873936
Platelet-derived exosomes mediate platelet atherogenic interactions with endothelial cells and monocytes. A new method for isolation of plasma platelet-derived exosomes is described and used to examine effects of aging and...
2.
Luk F, Kim R, Li K, Ching D, Wong D, Joshi S, et al.
J Cardiovasc Pharmacol
. 2015 Sep;
67(1):47-56.
PMID: 26322923
Aims: We recently reported that immunosuppression with FTY720 improves cardiac function and extends longevity in Hypomorphic ApoE mice deficient in scavenger receptor Type-BI expression, also known as the HypoE/SR-BI(–/–) mouse...
3.
Yeghiazarians Y, Honbo N, Imhof I, Woods B, Aguilera V, Ye J, et al.
J Cardiovasc Pharmacol
. 2014 May;
63(5):406-11.
PMID: 24805144
Cardiovascular disease is the leading cause of death in Western countries. A major limitation of current treatments is the inability to efficiently repair or replace dead myocardium. Recently, stem cell-based...
4.
5.
Wang G, Kim R, Imhof I, Honbo N, Luk F, Li K, et al.
J Cardiovasc Pharmacol
. 2014 Feb;
63(2):132-143.
PMID: 24508946
FTY720, an analogue of sphingosine-1-phosphate, is cardioprotective during acute injury. Whether long-term FTY720 affords cardioprotection is unknown. Here, we report the effects of oral FTY720 on ischemia/reperfusion injury and in...
6.
7.
Lovett D, Mahimkar R, Raffai R, Cape L, Zhu B, Jin Z, et al.
PLoS One
. 2013 Jul;
8(7):e68154.
PMID: 23874529
Matrix metalloproteinase-2 (MMP-2) is increasingly recognized as a major contributor to progressive cardiac injury within the setting of ischemia-reperfusion injury and ischemic ventricular remodeling. A common feature of these conditions...
8.
Kawabori M, Kacimi R, Karliner J, Yenari M
World J Cardiol
. 2013 May;
5(4):75-86.
PMID: 23675553
The sphingolipid metabolites ceramide, sphingosine, and sphingosine-1-phosphate (S1P) and its enzyme sphingosine kinase (SphK) play an important role in the regulation of cell proliferation, survival, inflammation, and cell death. Ceramide...
9.
Vessey D, Li L, Imhof I, Honbo N, Karliner J
Med Sci Monit Basic Res
. 2013 Apr;
19:126-32.
PMID: 23567658
Background: We investigated the hypothesis that postconditioning by FTY720 (FTY) in isolated perfused mouse hearts is independent of the sphingosine 1-phosphate (S1P) pathway. Material And Methods: Ex vivo hearts were...
10.
Karliner J
Biochim Biophys Acta
. 2012 Jun;
1831(1):203-12.
PMID: 22735359
Activation of sphingosine kinase/sphingosine 1-phosphate (SK/S1P)-mediated signaling has emerged as a critical cardioprotective pathway in response to acute ischemia/reperfusion injury. S1P is released in both ischemic pre- and post-conditioning. Application...